Profile data is unavailable for this security.
About the company
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
- Revenue in USD (TTM)32.88m
- Net income in USD-108.91m
- Incorporated1995
- Employees183.00
- LocationSangamo Therapeutics Inc501 Canal Blvd.RICHMOND 94084United StatesUSA
- Phone+1 (510) 970-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.sangamo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 123.07m | 44.00 | -- | 2.71 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 127.05m | 24.00 | 6.15 | 1.01 | 5.82 | 1.82 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 127.37m | 13.00 | 3.18 | 0.6429 | 2.90 | 63.68 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 130.01m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 132.00m | 28.00 | -- | 1.02 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| AVITA Medical Inc | 71.61m | -48.59m | 132.02m | 226.00 | -- | -- | -- | 1.84 | -1.75 | -1.75 | 2.57 | -0.5446 | 1.05 | 1.69 | 6.86 | 316,854.00 | -71.40 | -- | -182.42 | -- | 83.27 | -- | -67.85 | -- | 0.4557 | -8.22 | 1.63 | -- | 11.45 | -- | 21.44 | -- | -- | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 132.16m | 183.00 | -- | 19.08 | -- | 4.02 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 132.40m | 32.00 | -- | 4.99 | -- | 3.27 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 132.65m | 131.00 | -- | 2.04 | -- | 12.63 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Vaxart Inc | 148.20m | -50.70m | 133.58m | 105.00 | -- | 4.76 | -- | 0.9013 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 133.68m | 22.00 | -- | 3.46 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 134.92m | 97.00 | -- | 1.25 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 142.38m | 21.00 | -- | 1.78 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 144.79m | 33.00 | -- | 7.06 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 144.88m | 147.00 | -- | 1.02 | -- | 15.59 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
Data as of Feb 18 2026. Currency figures normalised to Sangamo Therapeutics Inc's reporting currency: US Dollar USD
11.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.88m | 2.94% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 8.43m | 2.51% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.54m | 1.35% |
| Geode Capital Management LLCas of 31 Dec 2025 | 3.87m | 1.15% |
| Jane Street Capital LLCas of 31 Dec 2025 | 2.92m | 0.87% |
| Two Sigma Investments LPas of 30 Sep 2025 | 2.48m | 0.74% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 2.42m | 0.72% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 2.11m | 0.63% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 1.96m | 0.58% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 1.71m | 0.51% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
